210574-45-1

Upstream product

• 4771-80-6 1,2,5,6-tetrahydrobenzoic acid 
• 100-51-6 benzyl alcohol 
• 2100-17-6 4-pentenal 
• 621-84-1 O-benzyl carbamate 
• 140-88-5 ethyl acrylate 
• 4103-88-2 1-isocyano-3-cyclohexene 
• 3422-03-5 benzyloxycarbonyl azide 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 337361-98-5 (1β,3α,4α)-benzyl N-(3,4-dihydroxy-1-cyclohexyl)carbamate 
• 2655-68-7 3-Cyclohexenyl-1-amine 

Relevant academic research and scientific papers

Catalytic Decarboxylative C?N Formation to Generate Alkyl, Alkenyl, and Aryl Amines

Transition-metal-catalyzed sp2 C?N bond formation is a reliable method for the synthesis of aryl amines. Catalytic sp3 C?N formation reactions have been reported occasionally, and methods that can realize both sp2 and sp3 C?N formation are relatively unexplored. Herein, we address this challenge with a method of catalytic decarboxylative C?N formation that proceeds through a cascade carboxylic acid activation, acyl azide formation, Curtius rearrangement and nucleophilic addition reaction. The reaction uses naturally abundant organic carboxylic acids as carbon sources, readily prepared azidoformates as the nitrogen sources, and 4-dimethylaminopyridine (DMAP) and Cu(OAc)2 as catalysts with as low as 0.1 mol % loading, providing protected alkyl, alkenyl and aryl amines in high yields with gaseous N2 and CO2 as the only byproducts. Examples are demonstrated of the late-stage functionalization of natural products and drug molecules, stereospecific synthesis of useful α-chiral alkyl amines, and rapid construction of different ureas and primary amines.

TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS

Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating fibrosis in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating fibrosis

COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS

Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating cancer in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating solid and hematologic cancers.

Preparation method of beta-homoglutamic acid

The invention belongs to the field of preparation of organic compounds, and provides a preparation method of beta-homoglutamic acid. The method is characterized in that: 3-cyclohexenecarboxylic acid is used as a raw material, beta-homoglutamic acid is synthesized at a high yield through three the steps of reactions of Curtius rearrangement, olefin oxidation and protection group removal, and beta-homoglutamic acid with high yield and high optical purity can be obtained through configuration retention by using optically pure 3-cyclohexenecarboxylic acid. The method has the advantages of easily available raw materials, mild reaction conditions and low cost, and is suitable for large-scale preparation of beta-homoglutamic acid.

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

Synthesis of Pyridazine and Pyrrole Analogues of 2-Aminotetralin as Potential Dopaminergics

Syntheses of pyridazine and pyrrole analogues of 2-aminotetralin starting from 3-cyclohexene-1-carboxylic acid are reported. All syntheses involve the following key steps: Curtius rearrangement for amine functionality, inverse electron demand Diels–Alder

Functionalized Dialdehydes as Promising Scaffolds for Access to Heterocycles and β-Amino Acids: Synthesis of Fluorinated Piperidine and Azepane Derivatives

Functionalized dialdehydes are considered important substrates that can be transformed into various substituted heterocyclic, alicyclic, and polysubstituted compounds. Here, we report a robust stereocontrolled procedure for the synthesis of novel functionalized trifluoromethyl-containing piperidine and azepane derivatives, based on oxidative ring cleavage of the C=C bond of diversely substituted cycloalkenes, followed by reductive ring closure of the diformyl intermediates in the presence of fluorine-containing amines.

COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS

The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions and treatment methods or uses as antibacterials for bacterial infections.

Bismuth triflate-catalyzed addition of allylsilanes to N- alkoxycarbonylamino sulfones: Convenient access to 3-Cbz-protected cyclohexenylamines

Bismuth triflate was found to be an efficient catalyst in the Sakurai reaction of allyltrimethylsilanes with N-alkoxycarbonylamino sulfones. The reaction proceeded smoothly with a low catalyst loading of Bi(OTf) 3·4H2O (2-5 mol%) to afford the corresponding protected homoallylic amines in very good yields (up to 96%). A sequential allylation reaction followed by ring-closing metathesis delivers 6-8 membered 3-Cbz-protected cycloalkenylamines.

Two-directional cross-metathesis

Two-directional cross-metathesis of a range of α,ω dienes with a variety of electron deficient alkenes has been accomplished. It was found that the process is quite general and gives complete selectivity for the E,E-dienes, making this a very useful and h